MCID: ERY066
MIFTS: 29

Erythema Multiforme Major

Categories: Rare diseases, Skin diseases

Aliases & Classifications for Erythema Multiforme Major

MalaCards integrated aliases for Erythema Multiforme Major:

Name: Erythema Multiforme Major 58 6 71
Erythema Exsudativum Multiforme Majus 58
Erythema Multiforme Majus 58
Stevens-Johnson Syndrome 71

Classifications:

Orphanet: 58  
Rare skin diseases


External Ids:

Orphanet 58 ORPHA502499
UMLS 71 C0038325 C3241919

Summaries for Erythema Multiforme Major

MalaCards based summary : Erythema Multiforme Major, also known as erythema exsudativum multiforme majus, is related to erythema multiforme and severe cutaneous adverse reaction. An important gene associated with Erythema Multiforme Major is HLA-B (Major Histocompatibility Complex, Class I, B). The drugs Molgramostim and Ophthalmic Solutions have been mentioned in the context of this disorder. Affiliated tissues include eye, salivary gland and t cells.

Related Diseases for Erythema Multiforme Major

Graphical network of the top 20 diseases related to Erythema Multiforme Major:



Diseases related to Erythema Multiforme Major

Symptoms & Phenotypes for Erythema Multiforme Major

Drugs & Therapeutics for Erythema Multiforme Major

Drugs for Erythema Multiforme Major (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 43)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Molgramostim Investigational Phase 4 99283-10-0
2 Ophthalmic Solutions Phase 4
3
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
4
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
5
Coal tar Approved Phase 3 8007-45-2
6
Etanercept Approved, Investigational Phase 3 185243-69-0
7
Sargramostim Approved, Investigational Phase 2, Phase 3 123774-72-1, 83869-56-1
8
Lenograstim Approved, Investigational Phase 2, Phase 3 135968-09-1
9 Pharmaceutical Solutions Phase 2, Phase 3
10 Antifungal Agents Phase 3
11 Immunosuppressive Agents Phase 3
12 Immunologic Factors Phase 2, Phase 3
13 Anti-Infective Agents Phase 3
14 Cyclosporins Phase 3
15 Calcineurin Inhibitors Phase 3
16 Analgesics, Non-Narcotic Phase 3
17 Anti-Inflammatory Agents, Non-Steroidal Phase 3
18 Analgesics Phase 3
19 Adjuvants, Immunologic Phase 2, Phase 3
20
Folic acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 59-30-3 6037
21
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 1, Phase 2 83-88-5 493570
22 Nutrients Phase 1, Phase 2
23 Micronutrients Phase 1, Phase 2
24 Vitamin B Complex Phase 1, Phase 2
25 Trace Elements Phase 1, Phase 2
26 Vitamins Phase 1, Phase 2
27 Vitamin B2 Phase 1, Phase 2
28 Folate Phase 1, Phase 2
29 Vitamin B9 Phase 1, Phase 2
30 Photosensitizing Agents Phase 1, Phase 2
31
Benzocaine Approved, Investigational Phase 1 1994-09-7, 94-09-7 2337
32
tannic acid Approved Phase 1 1401-55-4
33 Anesthetics Phase 1
34 Anesthetics, Local Phase 1
35
Allopurinol Approved 315-30-0 2094
36
Isotretinoin Approved 4759-48-2 5538 5282379
37 Anti-Bacterial Agents
38 Immunoglobulin A
39 Immunoglobulins
40 gamma-Globulins
41 Immunoglobulins, Intravenous
42 Antibodies
43 Rho(D) Immune Globulin

Interventional clinical trials:

(show all 26)
# Name Status NCT ID Phase Drugs
1 Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye Completed NCT01488396 Phase 4 0.05%cyclosporin eye drop
2 Evaluation of G-CSF as a Treatment of Toxic Epidermal Necrolysis Recruiting NCT02739295 Phase 4 recombinant granulocyte - colony stimulating factor;NaCl 0.9%
3 NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. Completed NCT01696500 Phase 3 Intravenous immunoglobulin
4 Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Completed NCT00346450 Phase 3
5 NATIENS: A Phase III Randomized Double-Blinded Placebo Controlled Study to Determine the Optimal Management and Mechanisms of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Not yet recruiting NCT02987257 Phase 3 Harmonized supportive care;Cyclosporine 5 mg/kg bid days 0-14;Etanercept 50 mg sc day 0 and day 3
6 Evaluating the Therapeutic Efficacy of Filgrastim in Severe Bullous Drug Eruptions (Lyell and Stevens-Johnson Syndromes) Not yet recruiting NCT04651439 Phase 2, Phase 3 Filgrastim;Placebo
7 The Use of Riboflavin/Ultraviolet A Cross-linked Human Donor Corneas as Carriers for the Boston Keratoprosthesis Completed NCT01582880 Phase 1, Phase 2 Riboflavin
8 Mesenchymal Stromal Cells Treatment in Lyell Syndrome: A Pilot Phase 1-2 Open Trial Not yet recruiting NCT04711200 Phase 1, Phase 2 Adipose derived stromal cells intravenously injected
9 Palifermin Treatment of Toxic Epidermal Necrolysis Terminated NCT02037347 Phase 1, Phase 2 Palifermin
10 Infliximab Therapy to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis Withdrawn NCT01256489 Phase 1, Phase 2 Infliximab
11 Topical Infliximab in Autoimmune Eyes With Keratoprosthesis Withdrawn NCT02126020 Phase 1, Phase 2 topical infliximab
12 Pilot Study Comparing Remicade (Infliximab) vs. Standard Care in the Treatment of Toxic Epidermal Necrolysis Withdrawn NCT00372723 Phase 2 Remicaide (infliximab)
13 A Randomized Placebo Controlled Split-body Double-blind Phase II Clinical Trial to Investigate the Safety and Efficacy of Clobetasol 0.05% Ointment for the Treatment of Toxic Epidermal Necrolysis (TEN) Withdrawn NCT02319616 Phase 1, Phase 2 Clobetasol 0.05% ointment;Placebo
14 Platelet Rich-plasma in Management of Chronic Multiple Oral Ulcers Completed NCT03878771 Phase 1 Dermovate cream in Orabase
15 Comparison of Corneal Epitheliotropic Factors in Autologous Serum Eye Drops Between Nonautoimmune Dry Eye and Stevens-Johnson Syndrome With Dry Eye Unknown status NCT01122303
16 A Prospective Study to Prove the Usefulness of HLA-B*5801 Screening Test for the Prevention of Allopurinol-induced Severe Cutaneous Adverse Reaction in Patient With Chronic Kidney Disease Unknown status NCT03046914
17 The Multicenter Registry of Patients With Severe Cutaneous Adverse Reactions Among Tertiary Medical Institutes in Thailand Unknown status NCT02574988
18 Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study Unknown status NCT02795143 Isotretinoin
19 Salivary Gland and Labial Mucous Membrane Transplantation in the Treatment of Severe Symblepharon and Dry Eye in Patients With Stevens-Johnson Syndrome. Completed NCT01178242
20 Stevens-Johnson Syndrome Associated With Antimicrobial Completed NCT00844038
21 A Prospective Open-label, Multicenter Clinical Investigation to Assess the Safety and Performance of ARGOS-IO System in Patients Undergoing Implantation of a Boston Keratoprosthesis (BKPro) Completed NCT02945176
22 Adverse Cutaneous Drug Reactions Collection of Clinical Data and Biological Samples Recruiting NCT03659227
23 Association of Cytokines With the Development of Complications in Burn and Toxic Epidermal Necrolysis (TENS) Patients Recruiting NCT04252651
24 The Effects of Minor Salivary Gland Transplantation for Cicatrizing Conjunctivitis Recruiting NCT03839069
25 An Investigator-initiated Trial (IIT) on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation in Corneal Limbal Deficiency Patients Available NCT02149732
26 A Prospective Multicenter Cohort Study Assessing Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis Not yet recruiting NCT03585946 Site specific standard of care comparison

Search NIH Clinical Center for Erythema Multiforme Major

Genetic Tests for Erythema Multiforme Major

Anatomical Context for Erythema Multiforme Major

MalaCards organs/tissues related to Erythema Multiforme Major:

40
Eye, Salivary Gland, T Cells, Skin, Endothelial, Thymus, Bronchial Epithelium

Publications for Erythema Multiforme Major

Articles related to Erythema Multiforme Major:

(show top 50) (show all 3707)
# Title Authors PMID Year
1
HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children. 61 6
23588310 2013
2
Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. 6 61
21428768 2011
3
Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. 6 61
16538176 2006
4
HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. 61 6
15743917 2005
5
Medical genetics: a marker for Stevens-Johnson syndrome. 61 6
15057820 2004
6
The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. 6 61
8006430 1994
7
Severe Cutaneous Adverse Reactions to Anti-tuberculosis Drugs in Korean Patients. 61
33474859 2021
8
Long-term sequelae from Stevens-Johnson syndrome/toxic epidermal necrolysis in a large retrospective cohort. 61
32289398 2021
9
Acute pancreatic injuries: A complication of Stevens-Johnson syndrome/toxic epidermal necrolysis associated with cytotoxic immunocell activation. 61
32561372 2021
10
Amniotic membrane transplantation in a 2-month-old infant with toxic epidermal necrolysis. 61
33521381 2021
11
Mapping of susceptible variants for cold medicine-related Stevens-Johnson syndrome by whole-genome resequencing. 61
33574277 2021
12
Acute and chronic ophthalmic involvement, severity & sequelae in Stevens-Johnson syndrome and Toxic Epidermal Necrolysis. 61
33596622 2021
13
Recurrence of nivolumab-induced Stevens-Johnson syndrome due to tegafur/gimeracil/oteracil (TS-1®) after nivolumab discontinuation. 61
33586655 2021
14
Complete Fusion of Both Eyelids in Stevens-Johnson Syndrome: Case Report. 61
33528572 2021
15
Characteristic pathological features of keratinocyte death in a case of Stevens-Johnson syndrome manifested by an immune checkpoint inhibitor. 61
32780890 2021
16
Porphyria cutanea tarda exacerbation as a paraneoplastic syndrome in vaginal cancer resolved with chemoradiation. 61
33426257 2021
17
Human leukocyte antigen B*0702 is protective against ocular Stevens-Johnson syndrome/toxic epidermal necrolysis in the UK population. 61
33536518 2021
18
Treating toxic epidermal necrolysis with systemic immunomodulating therapies: A systematic review and network meta-analysis. 61
32898587 2021
19
Modeling the Bioactivation and Subsequent Reactivity of Drugs. 61
33496184 2021
20
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update. 61
32779747 2021
21
Toxic epidermal necrolysis in HIV-infected patients: are intravenous immunoglobulins really necessary in this subgroup? 61
33308088 2021
22
A Nationwide Study of Severe Cutaneous Adverse Reactions Based on the Multicenter Registry in Korea. 61
32961314 2021
23
Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text]. 61
32746624 2021
24
Carbamazepine-induced Stevens-Johnson syndrome in a patient with history of methotrexate-induced mast cell activation syndrome. 61
33505688 2021
25
Early high-dose intravenous corticosteroids rapidly arrest Stevens Johnson syndrome and drug reaction with eosinophilia and systemic symptoms recurrence on drug re-exposure. 61
32835874 2021
26
The effects of systemic cyclosporine in acute Stevens-Johnson syndrome/toxic epidermal necrolysis on ocular disease. 61
32445836 2021
27
SkinSerious: Disseminated intravascular coagulation complicating Stevens-Johnson syndrome and toxic epidermal necrolysis. 61
33515629 2021
28
Stevens-Johnson syndrome and toxic epidermal necrolysis associated with the use of macrolide antibiotics: a review of published cases. 61
32808293 2021
29
Biologic Treatment in Pediatric Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Systematic Review. 61
33422622 2021
30
[Two Cases of Stevens-Johnson Syndrome after Nivolumab Therapy for Gastric Cancer]. 61
33468752 2021
31
Human leucocyte antigen association of patients with Stevens-Johnson syndrome/toxic epidermal necrolysis with severe ocular complications in Han Chinese. 61
33441319 2021
32
Diagnosis of mycoplasma aetiology in Stevens-Johnson syndrome/toxic epidermal necrolysis. 61
32757268 2021
33
Real-time clinical note monitoring to detect conditions for rapid follow-up: A case study of clinical trial enrollment in drug-induced torsades de pointes and Stevens-Johnson syndrome. 61
33120413 2021
34
Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose. 61
32960100 2021
35
Spectrum of Nail Sequelae in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. 61
33295942 2021
36
A retrospective, 5-year, clinicoepidemiological study of severe cutaneous adverse reactions (SCARs). 61
33454956 2021
37
Sifting through the history of the nosology of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis and its clinicopathological relevance. 61
33252777 2021
38
The Role of IL-13, IL-15 and Granulysin in the Pathogenesis of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. 61
33560872 2021
39
Differences between Stevens-Johnson syndrome versus toxic epidermal necrolysis. 61
33252832 2021
40
Case Report: Successful Corneal Crosslinking in a Patient with Corneal Ectasia Associated with Stevens-Johnson Syndrome. 61
33394926 2021
41
A case of erythema multiforme major with multiple mucosal involvements in COVID-19 infection. 61
33226129 2021
42
Accuracy and Cost-effectiveness of a Telemedicine Triage Initiative for Patients With Suspected Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. 61
33237271 2021
43
Pharmacogenomics of Allopurinol and Sulfamethoxazole/Trimethoprim: Case Series and Review of the Literature. 61
33530463 2021
44
A beginner's guide to mucous membrane grafting for lid margin keratinization: Review of indications, surgical technique and clinical outcomes. 61
33510052 2021
45
Human Leukocyte Antigen Gene Testing and Carbamazepine-Induced Toxic Epidermal Necrolysis: A Study of Pediatric Practice. 61
32909461 2021
46
A 51-Year-Old Woman with Drug-Induced Hypersensitivity Syndrome Associated with Carbamazepine, Reactivation of Human Herpesvirus 6, and Acute Liver Failure: A Case Report. 61
33504758 2021
47
Successful Ocular Surface Reconstruction in Complete Ankyloblepharon With the Simple Oral Mucosal Epithelial Transplantation Technique: A Case Report. 61
33416218 2021
48
Paraneoplastic pemphigus associated with small lymphocytic lymphoma: A case report. 61
33466152 2021
49
The Role of In Vivo and Ex Vivo Diagnostic Tools in Severe Delayed Immune-Mediated Adverse Antibiotic Drug Reactions. 61
33453452 2021
50
Cutaneous eruption in COVID-19-infected patients in Thailand: An observational descriptive study. 61
33180327 2021

Variations for Erythema Multiforme Major

ClinVar genetic disease variations for Erythema Multiforme Major:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 HLA-B HLA-B*15:02 Variation risk factor 14909
2 HLA-B HLA-B, HLA-B*5801 Variation risk factor 14911

Expression for Erythema Multiforme Major

Search GEO for disease gene expression data for Erythema Multiforme Major.

Pathways for Erythema Multiforme Major

GO Terms for Erythema Multiforme Major

Sources for Erythema Multiforme Major

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....